Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Companion Pharmacogenetic Study to UMCC 9900/9901

This study has been terminated.
Information provided by:
University of Michigan Cancer Center Identifier:
First received: September 1, 2005
Last updated: March 24, 2008
Last verified: March 2008
The purpose is to examine the original breast tumor material to see how much of a metabolizing enzyme (CYP3A4) is present in tumor material. The researchers want to see if this is in any way associated with how the patient responded to docetaxel. They also want to examine the genes in the tumor that are responsible for the production of CYP metabolizing enzymes, to see if they are normal or if they have polymorphisms, or change compared to 'normal' CYP metabolizing enzymes.

Metastatic Breast Cancer

Study Type: Observational
Study Design: Time Perspective: Retrospective

Resource links provided by NLM:

Further study details as provided by University of Michigan Cancer Center:


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who participated on UMCC 9900/9901
  • Living patients must give written informed consent

Exclusion Criteria:

  • No tumor block tissue available
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00146029

United States, Michigan
University of Michigan Cancer Center
Ann Arbor, Michigan, United States, 48109
Sponsors and Collaborators
University of Michigan Cancer Center
Principal Investigator: Anne F. Schott, M.D. University of Michigan Cancer Center
  More Information Identifier: NCT00146029     History of Changes
Other Study ID Numbers: UMCC 3-27
Study First Received: September 1, 2005
Last Updated: March 24, 2008

Keywords provided by University of Michigan Cancer Center:
Patients who participated in UMCC 9900/9901 (Phase II Studies of Tailored-Dose Docetaxel in Metastatic Breast Cancer) processed this record on May 22, 2017